Bermuda’s Premier Leads Delegation to Consensus 2023
A delegation from Bermuda led by the Premier and Minister of Finance, the Hon. E. David Burt, JP, MP, will set off to Consensus, the world’s largest gathering of digital asset, blockchain and Web3 enthusiasts, in Austin, Texas this week.
Premier Burt will be speaking on Consensus’ main stage this Friday, 28 April, with Michael Casey, CoinDesk’s Chief Content Officer, on a keynote conversation entitled ‘Bermuda’s Strict but Progressive Path to Crypto Hub Status’. This speaking appearance will be preceded by Bermuda’s inaugural networking reception at Consensus, presented by the Bermuda Business Development Agency, in partnership with Walkers, RELM and NEXT Bermuda.
Premier Burt said, “I am pleased to be leading this mission to Consensus on behalf of the Government of Bermuda. Bermuda is leading the ‘race to top’ when it comes to providing regulatory clarity to digital asset businesses. And this week’s announcement that Coinbase, the largest cryptocurrency exchange in the U.S. has received their full license from the Bermuda Monetary Authority is further proof that global companies are taking note of this. The Government of Bermuda looks forward to supporting the ongoing evolution of global financial services and – there isn’t any better place for this to occur than here in our growing ecosystem.
“We also look forward to supporting the continued growth of our local fintech industry, with more global companies coming to our shores, creating opportunities for Bermudians to join in this exciting industry that is taking shape right here in Bermuda.”
David Hart, BDA CEO said, “The timing of this business development mission to Consensus could not be more perfect as it comes on the heels of Coinbase’s recent announcement that it has received its full digital asset business licence from the Bermuda Monetary Authority (BMA). We are looking forward to connecting with many innovative companies at Consensus to share Bermuda’s attributes as a safe and secure domicile offering regulatory and legal clarity to quality FinTech companies looking to set up shop in a blue-chip domicile.”
These activities all build on announcements made at Consensus last year including the formation of Bermuda’s first digital asset business industry group, NEXT Bermuda and that Jewel Bank became Bermuda’s first new bank in over 20 years after it was issued its combined full banking licence and digital asset business licence.
The BDA, BMA and other members of the Bermuda delegation will hold business development meetings with business leaders who have expressed an interest in joining Bermuda’s FinTech ecosystem. If you wish to arrange a meeting with the Bermuda delegation, email info@bda.bm.
The Bermuda Reception will be held on Thursday 27 April from 5 pm to 7.30 pm at Cedar Door, on 201 Brazos Street, in Austin and will feature signature Gosling’s cocktails and entertainment by Bermudian Gianluca Gibbons & Trio (featuring singer and "Bel-Air" actress Simone Joy Jones). Reception attendees will be entered in a draw to win a trip for two to the BDA’s Bermuda Tech Summit in November, including airfare, hotel and delegate passes. If you are interested in attending the Bermuda Reception at Consensus, email events@bda.bm.
CONNECTING BUSINESS: The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005731/en/
Contact information
BDA:
Stuart Roberts, Director of Marketing & Communications
stuart@bda.bm, +1 441 707 0038
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom